(Q38754829)

6 September 2017

title

Repression of phosphoglycerate dehydrogenase sensitizes triple-negative breast cancer to doxorubicin (English)

1 reference

triple-negative breast cancer

6 September 2017

main subject

1 reference

Xia Zhang

1

1 reference

6 September 2017

Weijun Bai

series ordinal

2

1 reference

6 September 2017

publication date

29 July 2016

1 reference

Cancer Chemotherapy and Pharmacology

6 September 2017

published in

1 reference

6 September 2017

volume

78

1 reference

6 September 2017

issue

3

1 reference

6 September 2017

page(s)

655-659

1 reference

Triple-negative breast cancer: therapeutic options

6 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3117-4

Genetic susceptibility to triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3117-4

The analysis of doxorubicin resistance in human breast cancer cells using antibody microarrays

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3117-4

Targeting triple-negative breast cancer: optimising therapeutic outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3117-4

Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3117-4

Genetic selection for enhanced serine metabolism in cancer development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3117-4

Serine is a natural ligand and allosteric activator of pyruvate kinase M2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3117-4

Serine starvation induces stress and p53-dependent metabolic remodelling in cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3117-4

Cancer cell killing via ROS: to increase or decrease, that is the question

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3117-4

Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3117-4

Functional genomics reveal that the serine synthesis pathway is essential in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3117-4

Functional interplay between the DNA-damage-response kinase ATM and ARF tumour suppressor protein in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3117-4

Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3117-4

The antitumor anthracyclines doxorubicin and daunorubicin do not inhibit cell growth through the formation of iron-mediated reactive oxygen species.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3117-4

Doxorubicin acts via mitochondrial ROS to stimulate catabolism in C2C12 myotubes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3117-4

Doxorubicin induces apoptosis in normal and tumor cells via distinctly different mechanisms. intermediacy of H(2)O(2)- and p53-dependent pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3117-4

10.1007/S00280-016-3117-4

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

6 September 2017

1043529010

0 references

1 reference